Ashwagandha (Withania somnifera): Evidence and Legal Status

Ashwagandha at a glance

Ashwagandha is Withania somnifera, a shrub of the nightshade family whose root is used in Ayurvedic medicine. Meta-analyses report lower stress and anxiety scores, slightly better sleep and better aerobic endurance, though the stress and anxiety evidence was rated low certainty. Case reports link it to liver injury. Denmark does not allow its sale as food, and Germany’s risk assessment institute advises several groups not to take it.

Evidence: Human trials · Updated 20 November 2026

What ashwagandha is

Withania somnifera, also called Indian ginseng or winter cherry, is an evergreen shrub of the nightshade family, Solanaceae. It grows in India, the Middle East and parts of Africa. Ayurvedic medicine uses mainly the root. Withanolides, a group of steroidal lactones, and alkaloids are considered its main active compounds.

Supplements use root powder or extracts, and some use the leaves. Both the plant part and the extraction method change how much of each compound a product contains.

KSM-66 is a branded root extract from the ingredient maker Ixoreal BioMed. Trials describe it as a water-based extract of the root only, standardised to at least 5% withanolides.

How ashwagandha works

Ashwagandha is sold as an adaptogen, a plant said to help the body cope with stress. Which compounds cause its effects, and at what amounts, is not known: Germany’s Federal Institute for Risk Assessment (BfR) could not identify them from the available data.

Several trials measured cortisol, the main stress hormone. A 2025 meta-analysis of seven trials found cortisol 1.16 µg/dL lower than with placebo. Across six trials in the same review, perceived stress showed no clear change. The BfR also points to possible effects on thyroid and sex hormones and on blood glucose.

Evidence

Our evidence labels describe the ingredient, not a product; see how we review.

Exercise. A 2026 meta-analysis pooled 13 trials with 599 participants, mostly young adults or athletes. Ashwagandha improved performance on average, most consistently aerobic endurance. Strength effects were positive but uncertain, and the range of results expected in a new trial included no effect.

In 57 men aged 18 to 50 with little resistance-training experience, KSM-66 was given at 600 mg a day for eight weeks. Bench press rose by 46.0 kg, against 26.4 kg with placebo. Leg extension rose by 14.5 kg against 9.8 kg, and arm and chest size grew more. Testosterone rose by 96.2 ng/dL against 18.0 ng/dL. For two other plants sold for testosterone, see our fenugreek and tribulus cards.

Stress and anxiety. A 2022 meta-analysis of 12 trials with 1,002 adults aged 25 to 48 found lower anxiety and stress scores than with placebo. The authors rated the certainty of that evidence low. In an earlier KSM-66 trial, 64 adults with chronic stress took 600 mg a day for 60 days; their stress scores and serum cortisol fell against placebo.

Sleep. A 2021 meta-analysis of five trials with 400 adults found a small but significant improvement in overall sleep. It was clearer in people with insomnia, at 600 mg a day or more and after at least eight weeks. The authors note that data on serious side effects are limited. For a different sleep ingredient, see our melatonin card.

Safety. A case series from Iceland and the US described five people who developed jaundice 2 to 12 weeks after starting ashwagandha supplements. None had liver failure. In four of them, liver tests returned to normal within one to five months; the fifth was lost to follow-up. The BfR flags possible interactions with medicines for blood glucose, blood pressure and the immune system, and it advises several groups against use (see the status box). Check with a doctor first if you take any of these or have a thyroid condition.

Amounts on labels

No Hammer Labz label in our files names ashwagandha. An ashwagandha label can name root powder, a root extract or a leaf extract, with or without a withanolide percentage. The weight then refers to the powder or extract, not to withanolides.

Trials used 600 mg of KSM-66 a day: for eight weeks in men doing resistance training, and for 60 days in adults with chronic stress. In the 2026 exercise meta-analysis, the authors call their dose analyses hypothesis-generating; the most evidence-supported range was 500 to 600 mg of extract a day.

Legal and anti-doping status

Status checked on 20 November 2026.

  • WADA: ashwagandha is not named on the 2026 or 2027 WADA Prohibited List.
  • EU novel food catalogue: all parts of the plant are listed as not novel in food supplements, and a non-concentrated water infusion of the root as not novel in food.
  • EU health claims: the EU list of permitted health claims (Regulation 432/2012) contains no claim for ashwagandha.
  • EU herbal medicines: in 2013, EMA’s herbal committee could not establish a monograph on the root. It found too little evidence to describe the herbal preparations and to show 30 years of medicinal use, 15 of them in the EU.
  • EU level: in June 2024, a working group of the heads of national food safety agencies put ashwagandha on a list of 13 substances proposed for an EU procedure. Such a procedure can end in a ban or a restriction on use in food. The group cited possible effects on reproduction, thyroid hormones and the immune system, and liver toxicity. The European Commission listed no such procedure for ashwagandha on 20 November 2026. Annex III of the regulation, its list of banned, restricted and monitored substances, does not name ashwagandha either.
  • Denmark: selling ashwagandha as food is illegal. The Danish Veterinary and Food Administration bases this on a risk assessment by the Technical University of Denmark. That assessment found negative effects on sex hormones and reproduction in men and women, and possible effects on metabolism and the immune and nervous systems.
  • Poland: a 2020 opinion of the Food Supplements Panel of the State Sanitary Inspection sets out conditions it considers appropriate for adult supplements. Powdered root stays below 3 g a day, and withanolides at no more than 10 mg in the daily portion. The panel also recommends a label warning against use with sedative, sleep or anti-epileptic medicines, and by children and pregnant or breastfeeding women.
  • Germany: in September 2024, the BfR advised children, pregnant and breastfeeding women and people with liver disease not to take ashwagandha supplements. It advised other groups to be cautious. This is advice, not a ban.
  • UK: the Food Standards Agency ran a call for evidence in 2024 and passed it to the Committee on Toxicity. The committee discussed a third draft statement in September 2026, and no final statement had been published by 20 November 2026.

Status differs by country and changes over time.

Found in

Haya Labs

  • Ashwagandha (90 capsules)
  • Ashwagandha KSM-66 (90 capsules)

We have not seen the Haya Labs labels, so we give no amounts.

Sources

  1. Fødevarestyrelsen (Danish Veterinary and Food Administration). Ashwagandha i kosttilskud og drikkevarer. Accessed 20 November 2026.
  2. German Federal Institute for Risk Assessment (BfR). Ashwagandha: food supplements with potential health risks. Communication 39/2024, 10 September 2024. Accessed 20 November 2026.
  3. Chandrasekhar K, Kapoor J, Anishetty S (2012). A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian J Psychol Med, 34(3), 255–262. PMID: 23439798.
  4. Wankhede S, Langade D, Joshi K, et al. (2015). Examining the effect of Withania somnifera supplementation on muscle strength and recovery: a randomized controlled trial. J Int Soc Sports Nutr, 12, 43. PMID: 26609282.
  5. Albalawi AA (2025). Dual impact of Ashwagandha: Significant cortisol reduction but no effects on perceived stress – A systematic review and meta-analysis. Nutr Health, 31(4), 1395–1408. PMID: 40746175.
  6. Li X, Li H, Yao S, et al. (2026). Effects of Withania somnifera (Ashwagandha) Supplementation on Exercise Performance: A Systematic Review and Three-Level Meta-Analysis. Nutrients, 18(12), 1915. PMID: 42356302.
  7. Akhgarjand C, Asoudeh F, Bagheri A, et al. (2022). Does Ashwagandha supplementation have a beneficial effect on the management of anxiety and stress? A systematic review and meta-analysis of randomized controlled trials. Phytother Res, 36(11), 4115–4124. PMID: 36017529.
  8. Cheah KL, Norhayati MN, Husniati Yaacob L, et al. (2021). Effect of Ashwagandha (Withania somnifera) extract on sleep: A systematic review and meta-analysis. PLoS One, 16(9), e0257843. PMID: 34559859.
  9. Björnsson HK, Björnsson ES, Avula B, et al. (2020). Ashwagandha-induced liver injury: A case series from Iceland and the US Drug-Induced Liver Injury Network. Liver Int, 40(4), 825–829. PMID: 31991029.
  10. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. In force from 1 January 2026. Accessed 20 November 2026.
  11. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2027. In force from 1 January 2027. Accessed 20 November 2026.
  12. European Commission. EU Novel Food status catalogue: Withania somnifera. Entry last modified 8 January 2024. Accessed 20 November 2026.
  13. European Union. Commission Regulation (EU) No 432/2012 establishing a list of permitted health claims made on foods. Consolidated text of 20 August 2025. Accessed 20 November 2026.
  14. European Medicines Agency, Committee on Herbal Medicinal Products. Public statement on Withania somnifera (L.) Dunal, radix. Final. EMA/HMPC/681519/2012, adopted 9 July 2013. Accessed 20 November 2026.
  15. Heads of European Food Safety Agencies, working group “Food Supplements”. First report of the HoA working group “Food Supplements”. Federal Office of Consumer Protection and Food Safety (BVL), 6 June 2024. Accessed 20 November 2026.
  16. European Commission. Addition of vitamins and minerals. Section on Article 8 of Regulation (EC) No 1925/2006. Accessed 20 November 2026.
  17. European Union. Regulation (EC) No 1925/2006 on the addition of vitamins and minerals and of certain other substances to foods. Annex III, consolidated text of 26 November 2025. Accessed 20 November 2026.
  18. Zespół do spraw Suplementów Diety (Food Supplements Panel, Poland). Uchwała nr 7/2020 w sprawie wyrażenia opinii dotyczącej stosowania Withania somnifera (L.) Dunal jako składnika suplementów diety. 7 February 2020. Accessed 20 November 2026.
  19. Food Standards Agency. Summary of responses to call for evidence on Ashwagandha. Published 25 June 2026. Accessed 20 November 2026.
  20. Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment. 8th September 2026 Committee on Toxicity Meeting. Accessed 20 November 2026.